AstraZeneca partners with PatientsLikeMe
pharmafile | April 14, 2015 | News story | Sales and Marketing | AstraZeneca, Lupus, PatientsLikeMe, Roche, diabetes, oncology, respiratory disease
AstraZeneca has signed a five-year agreement with PatientsLikeMe to give the pharma firm access to the latter’s global network of real-world data.
The arrangement allows AZ the chance to shape its main therapeutic areas, focussing initially on respiratory disease, lupus, diabetes and oncology.
“Understanding what patients are experiencing every day and how they define the value of their treatments are fundamental to our ability to push the boundaries of science in developing the next-generation of medicines,” says Briggs Morrison, who is an executive vice president at AstraZeneca.
“Our partnership with PatientsLikeMe will help us to harness the important perspectives of patients through their advanced technology and real-world, real-time evidence to support our research and development programmes.”
This isn’t the first deal of its kind for the patient network, as last year rival pharma firm Roche signed a similar agreement which gave it access to the service for pharma companies that delivers a range of tools.
This service includes enhanced and bespoke research services and capabilities, plus access to PatientsLikeMe’s clinical trial awareness tool, which allows patients to learn about clinical trials.
AZ will also be able to access a network of cross-sectional research and broader discovery of patient insights and focussed research projects to evaluate and develop new medical evidence.
Life Sciences Ventures’ executive vice president, Ed Godber concludes: “It’s rare to find a partner so committed to listening to and integrating the patient voice into the heart of its scientific development and operations.
“We’re excited to work together to transform the discovery and healthcare model and develop products and services tailored to what patients experience and truly need.”
Tom Robinson
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe
